Kessel-lo, Belgium

Damien Marchand

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 7.7

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2014-2016

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Damien Marchand

Introduction

Inventor Damien Marchand, based in Kessel-Lo, Belgium, has made significant contributions to the field of antiviral research. With a total of four patents to his name, his work primarily focuses on compounds that exhibit antiviral activity, particularly against the Human Immunodeficiency Virus (HIV). Marchand's innovative approach demonstrates the potential for developing effective treatments for viral infections in both humans and animals.

Latest Patents

Among Damien Marchand's notable patents is the invention titled "Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors." This invention encompasses a series of compounds designed to inhibit HIV replication. It outlines methods for synthesizing these compounds as well as novel intermediates that facilitate the preparation of such antivirals. The patent also discusses the formulation of pharmaceutical compositions containing these compounds and their potential use as medicines for treating HIV infections in animals. Another pertinent invention includes antiviral compounds integral to the same therapeutic application, highlighting the use of these compounds, often in combination with other antiviral agents, for the treatment of viral infections in animals.

Career Highlights

Damien Marchand is affiliated with Katholieke Universiteit Leuven, where he contributes to groundbreaking research in virology and medicinal chemistry. His dedication to developing antiviral therapies underscores the importance of academic contributions to public health and biomedical advancements.

Collaborations

In his research endeavors, Marchand collaborates with notable colleagues such as Patrick Chaltin and Zeger Debyser. This collaborative effort further enhances the development of antiviral agents, leveraging diverse expertise to tackle complex challenges in the field of viral infections.

Conclusion

Damien Marchand's innovative work and patents reflect a commitment to advancing antiviral treatments, particularly in the context of HIV. His ongoing collaborations and research initiatives at Katholieke Universiteit Leuven continue to pave the way for enhanced therapeutic options, ultimately contributing to global health improvements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…